Key result
Genetically predicted IL-6 signaling inhibition is linked to lower abdominal aortic aneurysm risk.
Why the study?
Does genetically predicted IL-6 signaling inhibition reduce the risk of abdominal aortic aneurysm?
Observational (n=1,492,971)
Yes
Does genetically predicted IL-6 signaling inhibition reduce the risk of abdominal aortic aneurysm?
Answers are grounded in this paper and cite their sources.
Human genetic evidence supports the clinical development of IL-6 signaling inhibition as a targeted medical therapy for abdominal aortic aneurysm.
BACKGROUND: Abdominal aortic aneurysm (AAA) represents a significant cause of mortality, yet no medical therapies have proven efficacious. The aim of the current study was to leverage human genetic evidence to inform clinical development of IL-6 (interleukin-6) signaling inhibition for the treatment of AAA. METHODS: gene region, are expressed per additional copy of the C allele, corresponding to the genetically predicted effect of IL-6 signaling inhibition. We consider genetic associations with AAA risk in the AAAgen consortium (39 221 cases and 1 086 107 controls) and UK Biobank (1963 cases and 365 680 controls). To validate against known effects of IL-6 signaling inhibition, we present associations with rheumatoid arthritis, polymyalgia rheumatica, and severe COVID-19. To explore mechanism specificity, we present associations with thoracic aortic aneurysm, intracranial aneurysm, and coronary artery disease. We further explored genetic associations in clinically relevant subgroups of the population. The association was similar for fatal AAA but with greater uncertainty due to the lower number of events. The association with AAA was of greater magnitude than associations with coronary artery disease and even rheumatological disorders for which IL-6 inhibitors have been approved. No strong associations were observed with thoracic aortic aneurysm or intracranial aneurysm. Associations attenuated toward the null in populations with concomitant rheumatological or connective tissue disease. CONCLUSIONS: Inhibition of IL-6 signaling is a promising strategy for treating AAA but not other types of aneurysmal disease. These findings serve to help inform clinical development of IL-6 signaling inhibition for AAA treatment.
No takes yet. Share an insight, caveat, or question.
Burgess et al. (2024) conducted an observational in Abdominal aortic aneurysm (AAA) (n=1,492,971). Genetically predicted IL-6 signaling inhibition was evaluated on Abdominal aortic aneurysm risk. In a genetic association study of 1,492,971 individuals, genetically predicted IL-6 signaling inhibition was associated with a reduced risk of abdominal aortic aneurysm.
Synapse has enriched 10 related papers. Consider them for comparative context: